Sapiens (SPNS: US) - 1Q16 Results

Makor Securities Makor Securities London Ltd (Paris Rep. Office) 336 rue Saint Honore 75001 Paris, FRANCE +33 1 42 33 02 05 Makor Capital Markets Makor Securities London Ltd (Geneva Rep Office) 27 rue de la Croix-d’Or 1204 Geneve, SWITERLAND +41 223 106 916 Makor Capital Rogovin Tower Menachem Begin 11 52689 Ramat Gan, ISRAEL +972 3 545 3777 Makor Securities London Ltd 7/8 Savile Row 2nd Floor London W1S 3PE, ENGLAND +44 207 290 5777 ISRAELI TECH SAPIENS INTERNATIONAL CORPORATION N.V. (NASDAQ:SPNS) May 13, 2016 Sapiens International Corporation (SPNS: US) 1Q results – Solid start to the year; Maintaining overweight and $13 Price Target Sapiens (SPNS: US) posted a solid start to the year with double digit top line growth that beat the street and our estimate. Management reaffirmed its guidance for 2016 for revenue of $207-$211 million (street - $210 million), and operating margin at a range of 15.0% to 15.5%, in line with our estimates. We note that 2016 revenue guidance reflects 15%-18% top line growth while in Q1 revenue growth was 21%, leaving room for upside to forecast. New wins in the quarter - During the first quarter, the company announced a number of new wins that further expand its revenue base and enhance its competitive position. For example, Dentists' Provident, a leading provider of income protection insurance in the U.K. and Ireland, selected Sapiens' ALIS life solution to replace its current legacy system. Another example is Iconica, a UK based company, that selected Sapiens IDIT set of solutions. Management noted on the call that demand for the company’s products and services remains strong and it expects this momentum to continue throughout the year. 1Q results summary - SPNS reported 1Q16 fully diluted EPS of $0.12 on revenue of $49.6 million, ahead of our expectations of $0.11 EPS on revenue of $48.2 (Street - $0.12 EPS on $48.0 million revenue). Revenues rose 21% compared to 1Q15 driven once again by all geographies and product line diversity comprised of both new and existing customers. North America, which is an important growth market for the company, continued to grow nicely and was up 17% y/y (32% mix), Europe grew 23% y/y (57% mix) and APAC also grew 23% y/y (10% mix). Gross margin for the first quarter was 43.5% up from 43.1% in 1Q15 and in line with our expectation. Operating profit for 1Q16 of $7.3 million (14.8% margin) in line with our expectation, an increase of 27% y/y. Strong Balance sheet – As of March 2016, the company has cash, cash equivalents and securities investments of around $98.5 million (with no debt) reflecting approx. $2 per share (~16% of current market price). The company announced a cash dividend of $0.20 per share. As we mentioned in the past, we expect the company to use most of the cash in order to execute its M&A strategy (the company also has an existing $80m shelf which it could utilize to that effect). Valuation: Following 1Q results, we tweak our projections and we now expect FY16 Non GAAP diluted EPS of $0.51 (up from $0.50) on revenue of $210 million. For FY17 we maintain our EPS projection of $0.57 on revenue of $239 million. We also maintain our $13 price target which is based on 20x ex-cash P/E to our projected Non-GAAP FY17 EPS, plus $2 cash per share (and is also supported by a DCF model). As we mentioned in prior reports, SPNS has an attractive business model which is based on long engagement cycle thus creates strong visibility into the company’s revenues in the short and long term. The company has demonstrated strong execution over that last quarters, which we believe will continue in 2016. An M&A deal could also be a catalyst. We maintain our overweight rating. Company Description Sapiens is a leading global provider of software solutions for the insurance industry, with an emerging focus on the broader financial services sector. The company offers core software solutions for Property and Casualty/General Insurance, Life, Pensions and Annuities providers, allowing them to manage policy administration, claims management and billing functions. 5 6 7 8 9 10 11 12 13 4/155/156/157/158/159/1510/1511/1512/151/162/163/164/165/16 1 Year price chart

Makor Securities Makor Securities London Ltd (Paris Rep. Office) 336 rue Saint Honore 75001 Paris, FRANCE +33 1 42 33 02 05 Makor Capital Markets Makor Securities London Ltd (Geneva Rep Office) 27 rue de la Croix-d’Or 1204 Geneve, SWITERLAND +41 223 106 916 Makor Capital Rogovin Tower Menachem Begin 11 52689 Ramat Gan, ISRAEL +972 3 545 3777 Makor Securities London Ltd 7/8 Savile Row 2nd Floor London W1S 3PE, ENGLAND +44 207 290 5777 Research Disclaimer This publication has been prepared by Makor Capital Limited (“Makor Capital”) and is intended for professional or qualified investors only. Makor Securities London Ltd (“Makor Securities”)is distributing this material to its clients who are Eligible Counterparties or Professional Clients under FCA Rules. It may also be disseminated to persons who are Investment Professionals within the meaning of the Financial Services and Markets Act 2000 (Financial Promotion Order 2005). In the United States Makor Capital only distributes this material to major US institutional investors (as that term is defined in Rule 15 a-6 of the Securities and Exchange Act of 1934) and to SEC registered broker-dealers or banks acting in a broker –dealer capacity” If you do not fall into any of these categories you should disregard it. This research material is a marketing communication. It is not investment research and has not been prepared in accordance with legal requirements designed to promote the independence of investment research. It is not subject to any prohibition on dealing ahead of the dissemination of investment research. It has not been produced by Makor Securities. This material does not take into account the particular investment objectives, financial situation or needs of individual clients or other recipients. Before acting on this material, clients and other recipients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. This material should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This material is produced by research providers which Makor Securities believes to be reliable, but Makor Securities does not warrant or represent (expressly or impliedly) that it is accurate, complete, not misleading or as to its fitness for the purpose intended and it should not be relied upon as such. Opinions expressed will be the current opinions of those producing the research as of the date appearing on this material only. We expect those producing the material in this report to update it on a timely basis but can give no undertaking that they will do so and regulatory compliance or other reasons may prevent them from doing so (or us from disseminating updated material). Members and employees of Makor Securities London Ltd, employees of Makor Capital, Makor Capital Markets may from time to time have long or short positions in securities, warrants, futures, options, derivatives or other financial instruments referred to in this material. For Makor Securities, this information is set out in our Conflicts of Interest Policy which is available on request. Policies for the production of research from other research providers are available on request.Unless otherwise stated, share prices provided within this material are as at the close of business on the day prior to the date of the material. Neither the whole nor any part of this material may be duplicated in any form or by any means. Neither should any of this material be redistributed or disclosed to anyone without prior consent. This material is issued for general information and discussion purposes only. None of Makor Securities, Makor Capital, Makor Capital Markets accepts liability whatsoever for any direct, indirect or consequential loss or damage of any kind arising out of the use of all or any of this material. The services, securities and investments discussed in this material may not be available to, nor are suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and it should be noted that investment involves risk, including the risk of capital loss. Past performance is no guide to future performance. In relation to securities denominated in foreign currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and it should be noted that investment involves risk, including the risk of capital loss. Past performance is no guide to future performance. In relation to securities denominated in foreign currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable. Entities Makor Securities London Ltd is authorised and regulated by the Financial Conduct Authority (FCA registration number 625054) Makor Capital, company number 514456466, is incorporated in Israel and is a 100% held subsidiary of Makor Holdings Pte Ltd incorporated in Singapore. Makor Capital Markets SA, company number CH-660.2.999.011-0 is incorporated in Switzerland and is also a 100% held subsidiary of Makor Holdings Pte Ltd.

Sapiens (SPNS: US) - 1Q16 Results - Page 4